by admin | May 9, 2025 | Patient
Sign Up Stay informed about the latest advancements and helpful resources related to HYFTOR®, your ally in managing Facial Angiofibroma. By opting in, you will be the first to receive updates on new developments, clinical insights, and support tools tailored to...
by admin | May 8, 2025 | Patient
Understanding TSC and Facial Angiofibroma Tuberous Sclerosis Complex Tuberous sclerosis complex (TSC) is a rare disease. Only 1 in 6,000 children born in the United States may have TSC. The disease causes benign (noncancerous) tumors to grow throughout the body. These...
by admin | May 6, 2025 | Patient
Support & Resources Getting Started We believe that every patient deserves clear information and seamless access to their treatment journey with HYFTOR® to treat Facial Angiofibroma. Our dedicated team is here to empower you with the resources you or your child...
by admin | May 5, 2025 | Patient
An FDA-Approved Topical Gel HYFTOR® is a clear gel that contains 0.2% of the prescription medication sirolimus (an mTOR inhibitor). It is the first and only topical medication approved by the Food and Drug Administration (FDA) to treat facial angiofibroma in tuberous...
by admin | Mar 31, 2025 | Patient
The first and only topical gel for the treatment of Facial Angiofibroma in tuberous sclerosis complex (TSC) approved by the Food and Drug Administration for adults and children 6 years and older HYFTOR® is a clear gel that containsthe mTOR inhibitor sirolimus. Not an...
Recent Comments